CHUGAI PHARMACEUTICAL CO.,LTD.｜INNOVATION BEYOND IMAGINATION

Apr 3, 2017 Caution Regarding False Solicitations on Behalf of Chugai
Apr 3, 2017 Warning against "Phishing" e-mails and social networking sites using the name of Chugai Pharmaceutical

News Releases
What's New

Sep 11: CSR
Contribution of Para-transit Vehicles to Welfare Services
Sep 08: CorporateProduct
Filing of Lawsuit on Patent Infringement Concerning Herceptin^® Injection, and a Petition for Provisional Disposition Order
Aug 25: ProductR&D
Approval of Actemra^®for Additional Indications of
Takayasu Arteritis and Giant Cell Arteritis,
Both are Designated Intractable Diseases
Aug 24: R&D
Chugai’s Emicizumab Receives Priority Review Designation by FDA
for Hemophilia A with Inhibitors
Aug 23: R&D
New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab

More

Jul 31: Webcast of Investor Conference on FY2017 2Q Financial Results
Jul 28: Investor Conference on FY2017 2Q Financial Results
Jul 27: Financial Results for Second Quarter of Fiscal Year 2017 (January - June, 2017)
Jul 20: Events & Presentations has been updated with the Time of the Financial Results
Jul 14: Webcast of R&D Conference Call (ISTH 2017)

Share Price

TSE Code 4519

Share Graph

Video Introduction of CHUGAI

Videos & Advertisements

Back to top

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Share Price

Top Message

R&D

Development
Pipeline

CSR

Recruit

Video Introduction of CHUGAI

Share Price

Top Message

R&D

DevelopmentPipeline

CSR

Recruit

Video Introduction of CHUGAI

Development
Pipeline